Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04871035 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)

Study acronym: IPET-GBS
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: May 4, 2025 to Sep 1, 2027v5
  2. Primary and study completion dates: May 4, 2023 to May 4, 2025v4
  3. Re-verified, no change to tracked fieldsv3
  4. Primary completion date: May 4, 2021 to May 4, 2023v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.
Trial Details
NCT Number NCT04871035
Lead Sponsor University of Ulm
Collaborators: DiaMed GmbH
Conditions
(from sponsor)		 GBS
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov